AAD: oxymetazoline, dapsone and light therapy

Written by on April 7, 2009 in in the news with 1 Comment

As promised in my 67th AAD Meeting SFO, rosacea highlights news item, here are some updates from the conference proceedings and handouts. In this update we’ll look at how Dr. Downie mentions the new and future possible treatments for rosacea. This is encouraging, to see dermatologists discussing what is new and potentially interesting in the field of rosacea.

SYM S048, Treatment of Acne and Rosacea in Ethnic Patients, Jeanine B. Downie, M.D., FAAD, Director, image Dermatology P.C., Assistant Attending Mountainside and Overlook Hospitals, Montclair, New Jersey.

Disclosures: Johnson & Johnson, Allergan (Shareholder), Medicis, Galderma, Novartis, Intendis, Skin Medica, Stiefel, Merz.

Slide 17: Oxymetazoline

  • Selective Alpha-1a adrenergic receptor agonist
  • Topical use of 0.05 percent was used to treat five patients with erythematotelangiectatic rosacea
  • Outcomes showed improvements in erythema and a reduction in erythematous flares for up to two years
  • The appearance of fine pink/red telangiectasias also improved with no evidence of tachphylaxis, rebound or adverse events
  • These results are exciting, but more rigorous studies are needed by Aspect Pharmaceuticals

(DT, Aug. 2008 Vol. 29, No. 8, p. 32).

Slide 18: Kinerase

  • Contains N6-furfuryladenine, synthetic Kinetin, which is a plant hormone that improves the skin barrier function and decreases erythema
  • Open label clinical trial with twice daily application of 0.1% Kinetin showed product well tolerated for mild to moderate rosacea
  • Shown efficacy in reducing redness

(Clin Exp Dermatol. Nov. 2007; 32(6): 693-695).

Slide 20: Topical Dapsone

  • Antimicrobial and anti-inflammatory properties
  • Effective for reduction of inflammatory lesions in acne and likely to be effective in rosacea
  • Continuous use of dapsone 5% gel not associated with an increase in plasma concentrations of the drug
  • No systematic safety concerns

(Kircik, L., Practical Dermatology, October 2008)

Slide 21: Light Therapy

  • Currently pulsed-dye (PDLs) or intense pulsed light (IPLs) are use to treat rosacea for skin types I-IV
  • There are recent studies combining light-emitting diode (LED) and either PDL or IPL to optimize outcomes
  • The combination therapy has a synergistic effect and works better than each one separately
  • Red LED lights have an anti-inflammatory effect and may decrease swelling
  • The IPL decreases erythema and decreases the number of vessels in the skin, this decreasing the flushing of the skin

(DT, Nov. 2008, Vol. 29, No. 11, p. 50).

Related Articles

Read more about: in the news

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. JL says:

    Yo lo probe y no me sirvio

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.